ClinicalTrials.gg
RecruitingNCT05602376Updated Nov 1, 2024

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

An interventional study of U=U testing messaging scripts and U=U adherence messaging scripts in HIV Infections, Men and Treatment Adherence, sponsored by Desmond Tutu HIV Foundation. Recruiting at 2 sites in South Africa. Open to male participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Desmond Tutu HIV Foundation · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,642
Allocation
Randomized
Ages
15 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 305 studies in HIV Infections with a site in South Africa — 15 open to participants now, 36 under way, 15 of them phase 3. HIV Infections · South Africa.

Planned enrollment
16th of 267
3,642 · median 280
Started
2023
with 9 others
No phase
49 of 305
8 open now
Primary completion
2026-12
later than 20 of 35 live
Registered
278th of 305
by date

Among the 305 studies in HIV Infections with a site in South Africa, this one is the 16th largest by planned enrollment of the 267 interventional ones that give a count, is one of 10 that started in 2023, is one of 49 with no phase, reaches primary completion later than 20 of the 35 other live ones, and was the 278th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 305 studies in HIV Infections with a site in South Africa are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 15 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 305 studies in HIV Infections with a site in South Africa, or all of them as a file.
02

Study summary

This study will evaluate the impact of U=U messaging and counseling on gaps in the HIV care cascade for men, including testing uptake and ART initiation (Aim 1), achieving viral suppression and retention in care (Aim 2) in two provinces in South Africa. The U=U message communicates the compelling idea that PLHIV who take ART and have an undetectable viral load (\<200 copies/mL) cannot sexually transmit HIV. Additionally, the investigators will conduct a multi-method evaluation to inform future implementation of U=U messaging interventions (Aim 3).

Read the detailed description

Increasing the coverage of HIV testing and treatment among people living with HIV (PLHIV) is essential for ending the global AIDS epidemic. Unfortunately, compared to women, men living with HIV (MLHIV) are less likely to know their HIV status, start anti retroviral treatment, or achieve viral suppression. Given that new HIV infections among women are driven, in part, by men's testing and treatment gaps, reducing the gender gap in testing uptake, treatment initiation and achievement of viral suppression by men must be prioritized in order to accelerate the decline in HIV incidence among women, improve men's HIV-related health outcomes and achieve the UNAIDS 95-95-95 goals by 2030.

In this study, the investigators evaluate the effectiveness of Undetectable Equals Untransmittable or "U=U" messaging for closing the gender gap in the HIV cascade. Particularly for men, the U=U message has the potential to accelerate progress towards the 95-95-95 targets by: 1) reducing anxiety associated with HIV testing (1st 95); 2) encouraging people who test HIV positive to initiate ART (2nd 95); and 3) reducing fear of transmitting HIV to sexual partners by promoting treatment adherence to achieve viral suppression (3rd 95). While there is a growing knowledge of Treatment as Prevention (TasP)/U=U among PLWH in Western countries, the reach and penetration of the U=U message in sub-Saharan Africa has been limited and few studies have tested the impacted of accessible U=U messages on ART uptake and adherence in sub-Saharan Africa.

Building on the investigators prior work on U=U messaging informed by behavioral economics and human-centered design, they propose to conduct two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2). The investigators will also conduct a multi-method evaluation to inform future implementation of U=U messaging interventions. To improve the generalizability of the findings, the study will be conducted in two provinces in South Africa (Western and Eastern Cape). If effective, the intervention can shape global HIV testing and treatment counselling guidelines and practices. The expert, multi-institutional collaborations will allow for the application of previous research findings, leverage unique implementation platforms and resources, and rapidly disseminate the findings.

03

Conditions studied

  • HIV Infections
  • Men
  • Treatment Adherence

Keywords

  • HIV
  • HIV testing
  • Men
  • U=U
  • Viral suppression
  • Treatment as Prevention
  • Viral load
  • ART uptake
  • Undetectable
  • Untransmittable
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

AIM 1:

  1. male
  2. aged ≥15 years
  3. present a study issued invitation card to site receptionist
  4. ability to provide .

AIM 2:

  1. cis-gender men
  2. aged ≥15 years
  3. newly initiating ART (i.e., treatment naïve) or re-initiating ART after 6 months of being lost-to-care
  4. live in Buffalo City or Cape Town Metro Health Districts
  5. provide written informed consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
3,642 participants (estimated)

Study arms

  • Experimental
    U=U testing messaging scripts

    Aim 1: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve HIV testing uptake by men

    Behavioral: U=U testing messaging scripts

  • Experimental
    U=U adherence messaging scripts

    Aim 2: Human-centred designed, behavioural nudge theory informed U=U messaging intervention to improve ART adherence, HIV viral suppression and retention in care

    Behavioral: U=U adherence messaging scripts

  • No intervention
    Standard of Care (SoC) messaging

    Aim 1: SoC messaging scripts will be used to both invite men for CB-HTS and to refer those that test HIV-positive for DoH clinic-based ART initiation Aim 2: SoC messaging as part of ART initiation counselling, and as part of their HIV care and treatment program

Interventions

  • BehavioralU=U testing messaging scripts

    On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health

  • BehavioralU=U adherence messaging scripts

    After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.

06

What researchers measure

Primary outcomes

  1. ART initiation among those invited to test for HIV

    Proportions of ART initiation among all people invited to test in each study arm over the year of Aim 1 data collection

    Time frame: 30-day follow-up period

  2. Proportion with viral load suppression

    Proportions of people who have documented viral suppression at the 6-month visit in each study arm during Aim 2

    Time frame: 6-month visit

Secondary outcomes

  1. % who agree to testing

    Proportions of testing uptake among all people invited to test in each study arm over the year of Aim 1 enrolment.

    Time frame: Baseline

  2. Proportion retained in care

    Proportions of people who have a recorded viral load at their 12-month visit in each study arm during Aim 2.

    Time frame: 12-month visit

07

Study locations

2 of 2 sites recruiting
  • Buffalo City Metro
    East London, Eastern Cape 5217, South Africa
    Recruiting
    • Andrew Medina-Marino, PhD · ContactAndrew.Marino@hiv-research.org.za · +27 87 821 1109
    • Andrew Medina-Marino, PhD · Principal investigator
    • Alison Buttenheim, PhD, MBA · Principal investigator
  • Cape Town Metro
    Cape Town, Western Cape 7405, South Africa
    Recruiting
    • Andrew Medina-Marino, PhD · ContactAndrew.Marino@hiv-research.org.za · +27 87 821 1109
    • Andrew Medina-Marino, PhD · Principal investigator
    • Alison Buttenheim, PhD, MBA · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form, Analytic code

Access criteria: Based on contractual agreement

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 45 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 2, 2022
StartActual
Mar 31, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05602376
Lead sponsor
Desmond Tutu HIV Foundation
Responsible party
Sponsor
First posted
Nov 2, 2022
Start date
Mar 31, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 1, 2024

Study contacts

Andrew Medina-Marino, PhD
Contact
Andrew.Marino@hiv-research.org.za
+27 87 821 1109
Andrew Medina-Marino, PhD
principal investigator · Desmond Tutu Health Foundation
Alison Buttenheim, PhD, MBA
principal investigator · Penn Nursing and Perelman School of Medicine, University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion